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sulin	 resistance	 and	 diabetes,	 but	 mechanisms	 underlying	 this	 relationship	 are	










clear whether they are merely associated with diabetes or if their 









et	 al.,	 2017).	A	number	of	 stimuli,	 including	potentially	oncogenic,	
inflammatory,	damage‐related,	and	metabolic	 stimuli,	 can	 trigger	a	
senescence	response	(Munoz‐Espin	&	Serrano,	2014).	Components	
of	the	SASP	secreted	by	adipose‐derived	senescent	cells	have	been	
postulated	 to	 confer	 insulin	 resistance	upon	metabolic	 tissues,	 in‐
hibit	 adipogenesis,	 and	 attract	 immune	 cells	 that	 can	 exacerbate	
insulin	 resistance	 (Xu,	 Palmer	 et	 al.,	 2015).	 Here,	 we	 determined	
whether removing senescent cells in the context of obesity improves 
metabolic phenotypes.
Recently,	drugs	that	preferentially	decrease	senescent	cell	bur‐
den,	 termed	 senolytics,	 have	 been	 identified	 (Kirkland,	 Tchkonia,	
Zhu,	Niedernhofer,	&	Robbins,	2017).	We	discovered	the	first	seno‐
lytics based on our observation that senescent cells rely on several 
survival	 pathways,	 including	 those	 regulated	 by	 PI3K/AKT‐,	 p53/
p21/serpine‐,	 HIF‐1α‐,	 and	 BCL‐2/BCL‐XL‐family	 components,	 to	
confer	resistance	to	their	pro‐apoptotic	SASP	and	 intracellular	cell	
damage	signals	(Zhu	et	al.,	2016,2015).	Knowing	this,	we	identified	
dasatinib	 (D)	and	quercetin	 (Q)	as	orally	bioactive	drugs	 that	 tran‐












for	 the	following	reasons.	 (a)	 In	our	hands,	no	senolytic	 investigated	
thus	 far	 targets	 all	 types	 of	 senescent	 cells	 (Kirkland	 &	 Tchkonia,	







tiple	 age‐	 and	 senescence‐associated	disorders,	 including	many	 that	
are	frequent	complications	or	comorbidities	of	diabetes	in	preclinical	
































and cardiac diastolic function improved with senolytic therapy. Our results implicate 
cellular	senescence	as	a	causal	factor	in	obesity‐related	inflammation	and	metabolic	
derangements and show that emerging senolytic agents hold promise for treating 
obesity‐related	metabolic	dysfunction	and	its	complications.
K E Y W O R D S
adipogenesis,	aging,	cellular	senescence,	dasatinib,	quercetin,	senolytics,	type	2	diabetes
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hyporeactivity,	osteoporosis,	 hepatic	 steatosis,	 physical	dysfunction,	
neurodegeneration,	 and	 neuropsychiatric	 dysfunction	 (Farr	 et	 al.,	











treatment	with	 the	 senolytics,	D	+	Q.	Our	 findings	 support	 the	 idea	
that senescent cells could be a novel therapeutic target for treating 
obesity‐induced	metabolic	dysfunction.
2  | RESULTS
2.1 | Senescent cells accumulate in visceral fat in 
obesity
We	 used	 two	 transgenic	 mouse	 models	 from	 which	 senescent	
cells	can	be	selectively	cleared:	(a)	p16‐3MR	mice,	in	which	a	long	
p16Ink4a‐promoter	 sequence	 drives	 expression	 of	 a	 trimodal	 re‐
porter‐killer	 fusion	 protein	 (3MR),	 allowing	 senescent	 cell	 killing	
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by	 ganciclovir	 (GCV)	 and	 identification	 by	 whole‐body	 lumines‐
cence	 (Demaria	 et	 al.,	 2014)	 and	 (b)	 INK‐ATTAC	 mice,	 in	 which	
a truncated p16Ink4a‐promoter	 sequence	 drives	 expression	 of	 a	
vFKBP‐caspase‐8‐FLAG	 fusion	 protein	 that	 can	 be	 activated	 by	
AP20187,	 a	 vFKBP	 dimerizer,	 to	 cause	 senescent	 cell	 apoptosis	
(Baker	et	al.,	2011).	Cells	that	highly	express	p16Ink4a are targeted 
in	the	INK‐ATTAC	and	p16‐3MR	models.	However,	not	all	cells	with	
high	 p16Ink4a	 expression	 are	 senescent,	 and	 not	 every	 senescent	
cell	 highly	 expresses	 p16Ink4a	 (Hall	 et	 al.,	 2017;	 Okuma,	 Hanyu,	
Watanabe,	&	Hara,	2017),	limiting	the	sensitivity	and	specificity	for	
senescent	cell	killing	in	these	mouse	models.	Therefore,	we	used	an	
additional	 distinct,	 potentially	 translatable	 approach	 for	 eliminat‐
ing	senescent	cells,	 that	 is,	 senolytic	drugs,	which	 target	anti‐ap‐
optotic	pathways	in	senescent	cells	and	do	not	depend	on	p16Ink4a 
F I G U R E  2  Eliminating	senescent	cells	enhances	glucose	homeostasis	and	insulin	sensitivity.	(a,	b)	Intraperitoneal	glucose	tolerance	









Means	±	SEM are shown. *p	<	0.05,	**p	<	0.005,	***p	<	0.0005;	one‐way	ANOVA	with	Bonferroni	correction	for	multiple	comparisons.	
#p	<	0.05,	two‐tailed	Student's	t	test	comparing	DIO	vehicle‐treated	group	to	DIO	ganciclovir‐treated,	or	D	+	Q‐treated	group.	Groups	of	
interest	were	compared	at	each	time	point	for	GTTs	and	ITTs






Senescent	 cell	 abundance,	 as	 measured	 by	 luciferase	 activity	 in	
p16‐3MR	mice,	 increased	 in	 response	 to	DIO	 compared	 to	 chow‐
fed	 mice	 (Figure	 1a–c	 and	 Supporting	 Information	 Figure	 S2a,b).	
Bioluminescent	imaging	(BLI)	in	ex	vivo	tissues	showed	that	the	most	
prominent	 signal	 was	 present	 in	 visceral	 (specifically	 perigonadal)	





depots,	 skeletal	muscle,	 liver,	 and	 pancreas	 (Figure	 1c).	 That	 said,	
limitations	of	BLI,	 including	a	high	threshold	to	visualize	senescent	
cells and limited tissue penetration of the Renilla luciferase	 signal,	
could have contributed to our inability to detect bioluminescence in 
these	other	 tissues.	Therefore,	we	used	additional,	more	 sensitive	
methods	 including	 gene	 expression,	 senescence‐associated	 beta‐
galactosidase	staining,	and	mass	cytometry	to	assess	senescent	cell	
abundance in the studies reported below.
2.2 | Senescent cell clearance improves glucose 
homeostasis and insulin sensitivity
Senescent	 cell	 abundance	 declined	 after	 intermittent	 administra‐
tion	of	ganciclovir	to	p16‐3MR	DIO	mice	(Figure	1a,b,d–f,),	AP20187	
to	DIO	INK‐ATTAC	mice	(Supporting	Information	Figure	S2c,d)	and	
INK‐ATTAC;	 db/db	 mice	 (Supporting	 Information	 Figure	 S2e),	 and	
D	+	Q	 to	 wild‐type	 DIO	 mice	 (Figure	 1g–i).	 CyTOF	 analyses	 con‐
ducted	 after	 a	 single	 course	 of	 AP20187	 or	 D	+	Q	 in	 INK‐ATTAC	
mice showed that adipose tissue senescent cells highly express‐
ing p16Ink4a‐promoter‐induced	FLAG,	CENP‐B,	 or	 p21Cip1 were de‐
creased	 significantly	 (Figure	 1j	 and	 Supporting	 Information	 Figure	
S2f).	 In	 these	 experiments,	 adipose	 progenitor	 cells,	 rather	 than	















ity,	 or	 food	 intake,	 consistent	with	 improved	 glucose	 homeostasis	
being	 due	 principally	 to	 increased	 insulin	 sensitivity	 (Supporting	
Information	Figure	S3m–r).
After	 senescent	 cell	 reduction,	DIO	mice	became	more	 insulin	
sensitive,	as	 indicated	by	insulin	tolerance	testing	(ITT;	Figure	2d,e	
and	 Supporting	 Information	 Figure	 S4a)	 and	 an	 increased	 glu‐
cose	 infusion	 rate	 during	 hyperinsulinemic	 clamping	 (Figure	 2g).	
Furthermore,	 AKT	 Ser473	 phosphorylation	 increased	 in	 response	
to ex vivo insulin stimulation of adipose tissue freshly harvested 
from	animals	that	had	undergone	senescent	cell	clearance	(Figure	2f	
and	 Supporting	 Information	 Figure	 S4b).	 The	 insulin‐positive	 pan‐
creatic islet area remained unchanged after depleting senescent 
cells	 (Supporting	 Information	 Figure	 S4c–e).	 Plasma	 insulin	 con‐
centrations were lower in response to a glucose challenge in both 
p16‐3MR	mice	treated	with	ganciclovir	and	DIO	mice	treated	with	
D	+	Q	 (Supporting	 Information	Figure	S4f,g).	Pancreatic	 insulin	se‐
cretion	was	unchanged	in	D	+	Q‐treated	mice	during	hyperglycemic	
clamping	 experiments	 (Figure	 2h).	 Insulin	 sensitivity	 was	 not	 af‐
fected by genetic interventions that cause elimination of senescent 
cells	in	age‐matched	lean	mice	(Supporting	Information	Figure	S4h)	
or	 obese	WT	mice	 (Supporting	 Information	 Figure	 S4i),	 indicating	
that	off‐target	effects	of	AP20187	or	ganciclovir	are	unlikely	to	have	
contributed substantially to the observed metabolic improvements. 
These	results	indicate	that,	at	least	using	these	methods	for	senes‐
cent	cell	ablation	in	mice	with	DIO‐induced	metabolic	dysfunction,	
metabolic benefits were primarily due to improved peripheral insulin 
sensitivity rather than β‐cell	compensation.	Hepatic	glucose	produc‐
tion	was	also	found	to	be	unchanged	upon	D	+	Q	treatment	in	DIO	
mice	 under	 basal,	 hyperglycemic,	 and	 hyperinsulinemic	 conditions	
(Figure	2i).	Our	 findings	do	not	preclude	 the	possibility	 that	other	
approaches for clearing senescent cells or at different stages during 
development	of	obesity‐induced	metabolic	dysfunction	might	affect	
hepatic glucose production or pancreatic insulin secretion.
2.3 | Adipogenic potential is improved after 
senescent cell reduction





ciclovir,	 plasma	 IFN‐γ	 and	 IL‐1β concentrations were decreased 
(Supporting	Information	Figure	S5a,b).	Cells	expressing	high	con‐
centrations	 of	 TNF‐α isolated from the visceral adipose tissue 
(VAT)	 stromal	 vascular	 fraction	 declined	 upon	 AP20187	 treat‐
ment	 of	 DIO	 INK‐ATTAC	 mice	 (Supporting	 Information	 Figure	
S5c).	 Plasma	 adiponectin,	which	 is	 associated	with	 improved	 in‐
sulin	 sensitivity	 (Kadowaki	 et	 al.,	 2006),	 also	 increased	 after	 se‐
nescent	cell	 reduction	 in	p16‐3MR	mice	 (Supporting	 Information	
Figure	 S5d,e),	 and	 adipose	 tissue	 IFN‐γ expression was reduced 
(Supporting	Information	Figure	S5f).
Activin	 A,	 a	 TGF‐β/GDF‐related	 protein	 that	 is	 a	 component	
of	 the	 senescent	 adipocyte	 progenitor	 SASP	 (Xu,	 Palmer	 et	 al.,	
6 of 15  |     PALMER Et AL.
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Means	±	SEM are shown. *p	<	0.05;	one‐way	ANOVA	with	Bonferroni	correction	or	two‐tailed	Student's	t test when comparing two groups
F I G U R E  4  Senescent	cells	promote	macrophage	infiltration.	(a)	Correlation	of	FLAG+	cells	with	F4/80+/Cd11b+	macrophages	in	the	SVF	
of	DIO	INK‐ATTAC	VAT	as	analyzed	by	CyTOF	(n	=	30).	(b)	Plasma	cytokines	in	ganciclovir‐treated	DIO	p16‐3MR	mice	(n	=	19–22	per	group).	
(c)	F4/80	mRNA	in	VAT	of	ganciclovir‐treated	p16‐3MR	DIO	mice	(chow	n	=	4,	DIO	n	=	17–22	per	group).	(d,	e)	F4/80+	crown‐like	structures	
in	VAT	of	ganciclovir‐treated	p16‐3MR	DIO	mice	(representative	photographs	in	d,	quantified	in	e;	chow	n = 4; DIO n	=	5–8	per	group).	(f)	
THP‐1	cell	migration	into	a	Transwell	containing	either	nonirradiated	or	irradiated	(senescent)	adipocyte	progenitors,	with	no	addition	of	
antibody	(control),	addition	of	nonspecific	antibody	(IgG),	or	addition	of	antibodies	against	MCP‐1,	MIP1‐β,	or	M‐CSF	(n	=	4	per	condition).	(g,	
h)	Representative	image	of	luminescence	signal	in	AP20187‐treated	INK‐ATTAC;db/db mice 24 hr following i.v. injection of 1 × 106 luciferase+ 
monocytes	(g),	normalized	to	vehicle‐treated	mice	and	quantified	in	h	(n	=	6	per	group).	(i)	Quantification	of	luminescence	in	D	+	Q‐treated	
db/db mice 24 hr following i.v. injection of 1 × 106 luciferase+	monocytes	isolated	from	CAG‐luc	mice,	normalized	to	vehicle‐treated	mice	
(n	=	5	per	group).	Means	±	SEM are shown. *p	<	0.05,	**p	<	0.005,	***p	<	0.0005;	one‐way	ANOVA	with	Bonferroni	correction	or	two‐tailed	
Student's	t test when comparing two groups
Chow DIO Vehicle DIO Ganciclovir
(a) (b) (c)
(d)




p16Ink4a‐promoter‐driven	 luciferase	 expression	 in	 p16‐3MR	 mice	
(Supporting	Information	Figure	S5g).	Activin	A	impedes	expression	
of	 the	 insulin‐sensitizing	 adipogenic	 transcription	 factors	 PPARγ 
and	 C/EBPα,	 thereby	 contributing	 to	 insulin	 resistance	 (Hamm,	
Jack,	Pilch,	&	Farmer,	1999;	Xu,	Palmer	et	al.,	2015;	Zaragosi	et	al.,	
2010).	Senescent	cell	ablation	abrogated	the	DIO‐induced	increase	
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in	activin	A	(Figure	3a,b).	This	was	associated	with	higher	expression	
of adipogenic transcription factors and their targets in adipocyte 
progenitors	from	obese	mice	(Figure	3c,d)	and	enhanced	adipogenic	
differentiation	 in	culture	 (Figure	3e).	These	findings	are	consistent	





by	 nonsenescent,	 proliferation‐competent	 adipocyte	 progenitors	
that	can	then	differentiate	into	insulin‐responsive	fat	cells.





adipose tissue distribution were mainly due to expansion of subcu‐
taneous	depots	(Supporting	Information	Figure	S5i,j).	Furthermore,	
DIO	INK‐ATTAC	mice	treated	with	AP20187	had	fewer	lipid	droplets	
in	muscle,	measured	by	oil	 red	O	staining	 (Supporting	 Information	
Figure	S5k),	and	less	severe	hepatic	steatosis	(Ogrodnik	et	al.,	2017).	
Collectively,	 these	 findings	 indicate	 that	decreasing	 the	burden	of	
senescent cells may enhance insulin sensitivity in part by improving 
the proliferative and differentiation potential of adipocyte progeni‐
tors,	contributing	to	healthier	adipose	tissue	distribution	and	limiting	
ectopic	lipid	deposition	(Gustafson	et	al.,	2015).
2.4 | Macrophage abundance is correlated with 




inflammatory	 mediators,	 including	 TNF‐α	 and	 osteopontin,	 which	
can	 contribute	 to	 obesity‐related	 insulin	 resistance	 (Tardelli	 et	 al.,	
2016;	Tesch,	2007).	Events	responsible	for	obesity‐related	immune	
cell	 infiltration	have	remained	 largely	elusive.	 In	VAT	of	DIO	mice,	
macrophage	 abundance	 correlated	with	 highly	 p16Ink4a‐expressing	
senescent	cells	(as	measured	by	p16Ink4a‐promoter‐induced	FLAG)	in	
vivo	(Figure	4a).
Treatment	 with	 ganciclovir	 in	 DIO	 p16‐3MR	 but	 not	 DIO	
wild‐type	 mice	 reduced	 plasma	 concentrations	 of	 the	 macro‐
phage‐attracting	chemokines,	MCP‐1	and	MIP‐1β,	as	well	as	macro‐
phage‐colony‐stimulating	factor	(M‐CSF)	(Figure	4b	and	Supporting	
Information	 Figure	 S6a).	 Expression	 of	 the	 macrophage	 marker,	
F4/80,	significantly	declined	 in	adipose	tissue	after	2–3	months	of	
intermittent	 treatment	 to	 remove	 senescent	 cells	 (Figure	 4c	 and	











senescent	 cells,	 macrophages	 can	 revert	 to	 a	 nonactivated	 state,	
potentially	even	into	monocytes	that	replicate.	Therefore,	we	con‐
ducted	 CyTOF	 studies	 and	 specifically	 assayed	 the	 macrophage	
markers,	F4/80	and	Cdllb,	and	verified	that	AP20187	and	D	+	Q	do	
not	 specifically	 and	 immediately	 target	 activated	macrophages,	 as	
this population did not decrease after one round of treatment with 
either	agent	(Supporting	Information	Figure	S2g,h).	 In	addition,	we	
have	 previously	 shown	 that	 D	+	Q	 treatment	 sufficient	 to	 reduce	
senescent preadipocyte abundance does not directly reduce mac‐
rophage abundance in freshly isolated adipose tissue explants from 
obese	human	subjects	(see	Supporting	Information	Figure	S9	in	Xu	
et	al.,	2018).
2.5 | Senescent cell clearance decreases 
macrophage homing to adipose tissue
We	 found	 that	 senescent	 adipocyte	 progenitors	 attract	 mono‐
cytes	in	culture	(Xu,	Tchkonia	et	al.,	2015;	Supporting	Information	
Figure	 S6i)	 and	 that	 this	 effect	 is	 mitigated	 by	 the	 addition	 of	
neutralizing	 antibodies	 against	 the	 SASP	 components	 MCP‐1	
and	MIP‐1β,	 but	 not	M‐CSF	 (Figure	 4f).	 To	 test	 whether	 senes‐
cent cells can directly cause immune cell infiltration and there‐
fore	 whether	 targeting	 senescent	 cells	 reduces	 subsequent	
macrophage	 burden	 in	 adipose	 tissue,	 we	 injected	 monocytes	
that constitutively express luciferase intravenously into lean and 
obese	 (db/db)	 nonluciferase‐expressing	 INK‐ATTAC	 or	 wild‐type	
mice.	We	used	db/db mice in these experiments due to their highly 
inflammatory	adipose	tissue	phenotype.	The	injected	cells	homed	
mainly	 to	 the	VAT	of	obese	mice,	where	obesity‐induced	 senes‐
cent	cells	concentrate,	with	little	to	no	luminescence	detected	in	







(h,	n	=	6–9	per	group).	Means	±	SEM are shown. *p	<	0.05,	***p	<	0.0005,	****p	<	0.0001;	one‐way	ANOVA	with	Bonferroni	correction	or	
two‐tailed	Student's	t test when comparing two groups
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lean	 mice	 (Supporting	 Information	 Figure	 S6j–l).	 Luciferase‐ex‐
pressing	 monocytes	 injected	 into	 obese	 INK‐ATTAC;db/db mice 
4	days	 after	 AP20187	 treatment,	 or	 into	 wild‐type	 db/db mice 
4	days	after	D	+	Q	treatment,	exhibited	decreased	migration	into	
VAT	 compared	 to	 vehicle‐treated	 mice	 (Supporting	 Information	
Figure	 4g–i).	 AP20187	 had	 no	 evident	 effect	 on	 monocyte	 mi‐
gration in control db/db mice	without	 the	 INK‐ATTAC	 transgene	
(Supporting	Information	Figure	S46m,n).	Thus,	senescent	cells	can	
10 of 15  |     PALMER Et AL.
cause	macrophage	migration	 into	 adipose	 tissue	 in	 obesity,	 and	
targeting senescent cells prevents and reduces the adipose tissue 
macrophage accumulation that is often associated with obesity.











plications of diabetes and obesity related to persistent inflammation 
caused	 by	 senescent	 cell	 accumulation,	 including	 cardiovascular	
and	 renal	 dysfunction.	 Indeed,	 senescent	 cell	 clearance	 enhanced	
diastolic	 function	 in	 obese	mice	 (Figure	 5a–c;	 systolic	 function	 as	
measured	by	 left	ventricular	ejection	 fraction	 [EF]	was	unchanged	
[Figure	5d]),	consistent	with	earlier	reports	in	other	models	that	se‐
nescent	 cells	 contribute	 to	 cardiac	dysfunction,	 vascular	 stiffness,	
and	atherosclerosis	 (Childs	et	al.,	2016;	Demaria	et	al.,	2017;	Roos	
et	 al.,	 2016;	 Zhu	 et	 al.,	 2015).	 Additionally,	 renal	 podocytes	 had	
increased	expression	of	Wilms	tumor	protein	 (Wt‐1),	a	measure	of	
podocyte	integrity	and	function	(Figure	5e;	Guo	et	al.,	2002),	after	
D	+	Q	 treatment,	which	also	decreased	p16Ink4a+ cells in renal cor‐
tex	 (Figure	5f).	 Furthermore,	we	 found	decreased	urinary	albumin	
to	creatinine	ratio	(ACR),	an	indicator	of	renal	dysfunction,	after	tar‐




certain currently available diabetes treatments.
3  | DISCUSSION
Our study indicates in several different models that senescent cell 
clearance may be an effective strategy for alleviating important ele‐
ments	of	obesity‐related	metabolic	dysfunction.	Senolytic	treatment	
recapitulated	metabolic	 improvements	 seen	after	 transgene‐medi‐
ated	clearance	of	senescent	cells.	Senescent	cells	may	not	only	drive	
insulin	resistance	directly	through	their	SASP,	but	also	promote	adi‐
pose tissue immune cell infiltration and impair progenitor cell func‐
tion.	More	investigation	is	needed	into	the	relative	contributions	of	






(Hall	 et	 al.,	 2017).	 These	 points	 suggest	 that	 interpreting	 studies	
based	on	 targeting	cells	with	high	expression	of	p16Ink4a alone re‐
quires	 caution,	 so	we	 also	 used	 senolytics	 to	 test	 our	 hypothesis.	
Effects	 of	 D	+	Q	 do	 not	 depend	 on	 high	 p16Ink4a	 expression,	 but	
rather on transiently disabling the survival pathways protecting se‐
nescent cells from apoptosis.
It is possible that other senolytic agents may have distinct or 
complementary	effects	to	those	of	D	+	Q	in	diabetes,	since	senolyt‐
ics vary considerably in the spectra of senescent cell types that are 
targeted.	Thus,	targeting	different	types	of	senescent	cells	and	de‐





cell types in patients with different constellations of symptoms and 
complications	of	metabolic	disease.	Another	key	step	will	be	to	test	





are	 underway.	 Indeed,	 the	 first	 clinical	 trial	 of	 senolytics	 was	 re‐










cell	 burden,	 rather	 than	 effects	 on	 senescence‐independent	 sig‐
naling	pathways,	 receptors,	or	enzymes	that	 require	 the	sustained	





4  | E XPERIMENTAL PROCEDURES
4.1 | Animals
Mice	 heterozygous	 for	 either	 the	 p16‐3MR	 or	 INK‐ATTAC	
transgenes	on	a	C57BL/6	background	were	used	in	these	experi‐
ments	 (Demaria	et	al.,	2017;	Xu,	Palmer	et	al.,	2015).	 J.L.K.,	T.T.,	
J.	 van	Deursen,	and	D.	Baker	 (all	 currently	at	Mayo)	devised	 the	
strategy	and	characterized	 INK‐ATTAC	mice	 (Baker	et	 al.,	 2011).	
The	ATTAC	 construct	was	 devised	 by	 P.	 Scherer,	who	 sent	 it	 to	
J.L.K.	 p16‐3MR	 mice	 were	 generously	 provided	 by	 Dr.	 Judith	
Campisi.	 Leptin	 receptor	 knockout	 heterozygotic	 (Leprdb/−)	 mice	
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were	 purchased	 from	 Jackson	 Laboratory	 (Bar	 Harbor,	ME)	 and	
crossed	to	either	p16‐3MR	mice	or	 INK‐ATTAC	mice	to	generate	
mice	homozygous	for	the	 leptin	receptor	mutation	(db/db).	CAG‐
luc	 transgenic	 C57BL/6	 mice	 were	 obtained	 from	 the	 Jackson	
Laboratory	 (Stock	 No:	 025854).	 The	 CAG‐luc	 mouse	 expresses	
firefly	 luciferase	 driven	 by	 the	 constitutively	 active	 CAG	 pro‐
moter	in	most	tissues.	Ages	of	mice	used	in	each	experiment	are	
reflected	 in	 Supporting	 Information	 Figure	 S1.	Male	 and	 female	
mice were used for db/db experiments.	Male	mice	were	used	for	
DIO	experiments	due	to	their	increased	susceptibility	to	high‐fat	
diet‐induced	 metabolic	 dysfunction.	 For	 diet‐induced	 obesity	
(DIO)	 experiments,	mice	were	maintained	 on	 a	 60%	 (by	 calorie)	
fat	diet	(D12492,	irradiated;	Research	Diets,	New	Brunswick,	NJ).	
Lean	 control	 mice	 were	 fed	 a	 normal	 chow	 diet	 (LabDiet	 5053,	
13.2%	fat	by	calorie,	St.	Louis,	MO).	Mice	were	maintained	under	
a	12‐hr	light	and	12‐hr	dark	cycle	at	24°C	with	free	access	to	food	















the last dose of one treatment round and the first day of the next 
treatment	round.	AP20187	(MedchemExpress,	Monmouth	Junction,	
NJ;	10mg/kg,	dissolved	 in	ethanol	 for	 stock	 solution,	 then	diluted	
in	PEG‐400	and	2%	Tween	for	dosing	solution)	or	PEG‐400/Tween	
2%	 in	 water	 (vehicle)	 was	 administered	 by	 i.p.	 injection	 for	 three	
consecutive	days,	with	12	days	between	treatments.	Dasatinib	(LC	
Laboratories,	Woburn,	MA;	5	mg/kg)	and	quercetin	(Sigma	Aldrich,	
St.	 Louis,	 MO;	 50	mg/kg)	 or	 vehicle	 (60%	 Phosal,	 10%	 ethanol,	
and	 30%	 PEG‐400)	 were	 administered	 for	 five	 consecutive	 days	
monthly via	oral	gavage	in	cohort	1,	or	for	three	consecutive	days,	
with 14 days between the last dose of one treatment round and the 
first	 day	 of	 the	 next	 treatment	 round	 in	 cohort	 2.	 For	CyTOF	ex‐
periments,	a	single	course	of	AP20187	(3	days)	or	D	+	Q	(5	days)	was	
given	3	days	prior	to	sacrifice.	Navitoclax	(Active	Biochem,	Kowloon,	
Hong	 Kong;	 50	mg/kg)	 or	 vehicle	 (60%	 Phosal,	 10%	 ethanol,	 and	






glucose	or	0.8	mU/kg	 insulin	 (i.p.)	 in	 the	early	afternoon	 following	
a	6‐hr	or	4‐hr	 fast,	 respectively.	Glucose‐stimulated	 insulin	 secre‐
tion	(GSIS)	in	DIO	and	lean	mice	was	measured	after	oral	gavage	of	
1.5	g/kg	 glucose	 following	 a	 4‐hr	 fast.	 Intraperitoneal	 injection	of	
glucose	was	used	for	GTT	due	to	increased	excursion	of	blood	glu‐
cose,	allowing	for	better	differentiation	between	treatment	groups.	
Oral administration of glucose was used for insulin secretion meas‐
urements	in	Figure	2h	to	ensure	the	most	physiologic	 induction	of	
insulin	secretion	(including	the	contribution	of	incretins),	as	well	as	to	
test the overall validity of our results by testing improvements with 
senescent	cell	clearance	in	multiple	assays.	For	db/db	mice,	glucose	
tolerance	 testing	was	performed	by	 injecting	1.0	g/kg	 glucose	 i.p.	
following	an	overnight	 fast.	Tail	 vein	blood	glucose	was	measured	
at time 0 and at indicated time points using a handheld glucometer 
(Bayer	Breeze	2	[Bayer,	Whippany,	NJ],	or	for	db/db mice,	AlphaTrak	
[Zoetis,	 Parsippany,	 NJ]).	 Aside	 from	 clear	 weight	 differences	 be‐










period	 in	which	only	glucose	 tracer	was	 infused,	 (b)	 a	hyperglyce‐
mic	period	(HGC)	in	which,	next	to	the	glucose	tracer,	glucose	was	
infused at a variable rate to maintain blood glucose levels at about 
20	mM,	and	(c)	a	hyperinsulinemic–euglycemic	period	(HIEC)	during	
which,	in	addition	next	to	the	glucose	tracer,	insulin	was	infused	at	a	
constant rate and glucose was infused at a variable rate to maintain 
blood	glucose	levels	at	about	6	mM.	During	all	three	periods,	blood	







We	designed	 a	 panel	 of	 antibodies	 based	on	 surface	markers,	 tran‐
scription	factors,	and	cytokines	(see	Supporting	Information	Table	S1).	
Each	antibody	was	tagged	with	a	rare	metal	isotope	and	its	function	
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verified	 by	mass	 cytometry	 according	 to	 the	 factory	manual	 (Multi	










genitors	 were	 defined	 as	 CD45−,	 CD31−,	 and	 Sca1+.	 Macrophages	
were	defined	as	F4/80+	and	CD11b+.	Endothelial	 cells	were	defined	
as	CD31+	and	CD146+.	T	lymphocytes	were	defined	as	CD4+	or	CD8+. 





















glass	slides	for	light	microscopy.	SA‐β‐gal+ cells as a percent of all nuclei 
were	quantified	in	at	least	10	images	taken	at	random	per	tissue	using	
NIS‐Elements	 software	 (Nikon	 Instruments,	 Melville,	 NY).	 Neither	
the	person	who	captured	images	for	quantification	nor	the	observer	




microscopy by measuring diameters of all completely visible adipo‐
cytes	per	field	using	Nikon	NIS‐Elements	software.






Albumin	 was	 measured	 by	 ELISA	 (GenWay,	 San	 Diego,	 CA),	 and	
creatinine	 was	 measured	 by	 colorimetric	 assay	 (MaxDiscovery;	
Bio	 Scientific,	Austin,	 TX)	 in	 urine	 collected	 from	nonfasted	mice.	
Albumin–creatinine	 ratio	 (ACR)	was	 calculated	by	determining	mi‐




plating and culture media designed to select against macrophage or 
endothelial	 cell	 contamination.	 Cells	were	 exposed	 to	 10	Gy	 radia‐
tion	or	were	sham‐irradiated.	After	25	days,	irradiated	cells	acquired	









progenitors were exposed to differentiation medium containing 
DMEM/F‐12,	 10%	 FBS,	 1μg/ml	 insulin,	 	 250	nM	 dexamethasone,	
0.5mM	 IBMX,	 	 and	 2.5μM	 rosiglitazone	 for	 48	 hours	 at	 20%	O2. 
Medium	was	then	replaced	with	DMEM/12	containing	only	10%	FBS	
and	insulin,	and	kept	in	culture	for	an	additional	5–8	days.
4.16 | Comprehensive laboratory animal 
monitoring system




Migration	 assays	 were	 performed	 using	 Transwell	 polycarbon‐
ate	membrane	 inserts	with	 a	5‐μm pore diameter purchased from 
Corning	 (Corning,	 NY).	 THP‐1	 cells	 were	 stained	with	 CellTracker	
CM‐DiI	 dye	 (Thermo	 Fisher	 Scientific,	 Waltham,	 MA)	 according	
to	 the	manufacturer's	 directions	 and	 then	 plated	 into	 the	 inserts.	
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Nonsenescent	control	or	senescent	human	primary	adipocyte	pro‐
genitors	were	seeded	into	the	bottom	chambers	of	the	plates.	After	
24	hr,	 DiI‐labeled	 THP‐1	 cells	 that	 had	 migrated	 into	 the	 bottom	
chamber were imaged.
For	 neutralizing	 antibody	 experiments,	 THP‐1	 cells	 (105)	 were	








Monocytes	 were	 isolated	 from	 femur	 and	 tibial	 bone	 marrow	 of	
CAG‐luc	transgenic	C57BL/6	mice	using	a	commercial	kit	(Monocyte	
Isolation	kit,	MACS	Miltenyi	Biotec,	San	Diego,	CA).	1	×	106 mono‐
cytes	in	PBS	were	injected	i.v.	via the tail vein in db/db or lean mice. 
Luminescent signal was examined 24 hr after monocyte injection.
4.19 | Luminescence imaging
Both	Renilla and firefly luminescence imaging were performed using 
a	Xenogen	IVIS	200	system	(Caliper	Life	Sciences,	Hopkinton,	MA).	
To	detect	p16‐3MR	Renilla	 luciferase‐expressing	cells,	200	µl	 coe‐
lenterazine	 h	 (Rediject,	 PerkinElmer)	 was	 injected	 i.p.	 into	 each	
mouse	10	min	before	imaging	was	initiated.	For	firefly	luminescence,	
3	mg	d‐luciferin	 (Gold	Biotechnology,	St.	Louis,	MO)	 in	200	µl	PBS	
was injected i.p. into each mouse 5 min before imaging was initiated. 
The	exposure	for	luminescence	images	was	5	min.
4.20 | Echocardiography
High‐resolution	 ultrasound	 imaging	 was	 used	 to	 evaluate	 cardiac	
function	as	previously	described	(Roos	et	al.,	2016).
4.21 | Anti‐Wilms tumor protein 
immunohistochemistry




Protein;	Abcam	#ab89901)	 diluted	1/100,	 followed	by	 a	 30‐min	 in‐
cubation	in	a	Ready‐to‐Use	HRP‐Labelled	secondary	antibody	(Dako	
K4003).	 Color	 was	 developed	 using	 Vector	 NovaRED	 Peroxidase	
Substrate	Kit	(SK‐4800)	followed	by	hematoxylin	counterstaining.
4.22 | Quantification and statistical analyses
When	comparing	two	groups,	unpaired	two‐tailed	Student's	t tests 







The	 authors	 are	 grateful	 to	 J.	 Armstrong	 for	 administrative	 as‐
sistance,	K.	Mantz	for	pancreatic	histology	analysis,	M.	Mahlman	
for	obtaining	human	adipose	samples,	and	C.	Inman	for	assistance	
with	 animal	 husbandry.	 This	work	was	 supported	 by	NIH	 grants	
AG13925	(J.L.K.),	AG041122	(J.L.K.),	AG31736	(Project	4:	J.L.K.),	
AG044396	 (J.L.K.),	 DK50456	 (J.L.K.,	 M.D.J.),	 AG46061	 (A.K.P.),	
AG51661	 (M.B.S),	 Minnesota	 Partnership	 for	 Biotechnology	
grant	MNP	IF	#14.06	(J.L.K.,	E.A.),	Robert	and	Arlene	Kogod,	the	
Connor	 Group	 (J.L.K.),	 Robert	 J.	 and	 Theresa	 W.	 Ryan	 (J.L.K.),	
the	Glenn	(J.L.K.,	N.K.L.),	Ted	Nash	Long	Life	(J.L.K.),	and	Noaber	
Foundations	 (J.L.K.),	 and	 BBSRC	 grants	 BB/K019260/1	 and	 BB/
M023389/1	 (M.O.,	 T.vZ.).	 Insulin	 and	 F4/80	 immunohistochem‐
istry	 was	 performed	 by	 the	 Ohio	 State	 University	 Comparative	
Pathology	&	Mouse	Phenotyping	Shared	Resource	(CPMPSR),	sup‐
ported	in	part	by	NCI	grant	P30	CA016058.	M.X.	received	the	sup‐
port	of	 the	Regenerative	Medicine	 Initiative	 for	Diabetes‐Career	
Development	 Award,	 the	 Glenn/AFAR	 Postdoctoral	 Fellowship	
for	Translational	Research	on	Aging,	and	an	Irene	Diamond	Fund/
AFAR	Postdoctoral	Transition	Award	in	Aging.	E.D.	was	supported	
by	 a	 stipend	 from	Noaber	 Foundation.	 A.K.P.	 received	 a	 Glenn/
AFAR	 Scholarship	 for	 Research	 in	 the	 Biology	 of	 Aging.	 A.K.P.	
thanks	the	Mayo	Clinic	Medical	Scientist	Training	Program	for	fos‐
tering	an	outstanding	environment	for	physician–scientist	training.












J.L.K.	 wrote	 the	 manuscript.	 All	 authors	 discussed	 the	 results	 and	
commented	on	the	manuscript.	J.L.K.	provided	overall	supervision.
R E FE R E N C E S
Baker,	 D.	 J.,	 Wijshake,	 T.,	 Tchkonia,	 T.,	 LeBrasseur,	 N.	 K.,	 Childs,	 B.	
G.,	 van	 de	 Sluis,	 B.,	 …	 van	 Deursen,	 J.	 M.	 (2011).	 Clearance	 of	
14 of 15  |     PALMER Et AL.















oral administration to humans. Drug Metabolism and Disposition: the 
Biological Fate of Chemicals,	36,	1357–1364.	https://doi.org/10.1124/
dmd.107.018267
Coppé,	J.‐P.,	Patil,	C.	K.,	Rodier,	F.,	Sun,	Y.	U.,	Muñoz,	D.	P.,	Goldstein,	
J.,	 …	 Campisi,	 J.	 (2008).	 Senescence‐associated	 secretory	 pheno‐
types	 reveal	 cell‐nonautonomous	 functions	 of	 oncogenic	RAS	 and	
the	p53	tumor	suppressor.	PLoS Biology,	6,	2853–2868.	https://doi.
org/10.1371/journal.pbio.0060301
Demaria,	 M.,	 Ohtani,	 N.,	 Youssef,	 S.	 A.,	 Rodier,	 F.,	 Toussaint,	 W.,	
Mitchell,	 J.	 R.,	 …	 Campisi,	 J.	 (2014).	 An	 essential	 role	 for	 senes‐
cent	 cells	 in	 optimal	wound	 healing	 through	 secretion	 of	 PDGF‐








related bone loss in mice. Nature Medicine,	23,	1072–1079.	https://
doi.org/10.1038/nm.4385
Graefe,	 E.	 U.,	 Wittig,	 J.,	 Mueller,	 S.,	 Riethling,	 A.‐K.,	 Uehleke,	 B.,	
Drewelow,	B.,	…	Veit,	M.	(2001).	Pharmacokinetics	and	bioavailability	




Reduced expression levels cause crescentic glomerulonephritis and 
mesangial sclerosis. Human Molecular Genetics,	11,	651–659.	https://
doi.org/10.1093/hmg/11.6.651
Gustafson,	 B.,	 Hedjazifar,	 S.,	 Gogg,	 S.,	 Hammarstedt,	 A.,	 &	 Smith,	
U.	 (2015).	 Insulin	 resistance	 and	 impaired	 adipogenesis.	 Trends 




beta‐galactosidase	can	be	 induced	 in	macrophages	as	part	of	a	 re‐
versible response to physiological stimuli. Aging,	9(8),	1867–1884.
Hamm,	 J.	K.,	 el	 Jack,	A.	K.,	 Pilch,	P.	 F.,	&	Farmer,	 S.	R.	 (1999).	Role	of	
PPAR	gamma	in	regulating	adipocyte	differentiation	and	insulin‐re‐
sponsive	glucose	uptake.	Annals of the New York Academy of Sciences,	
892,	134–145.	https://doi.org/10.1111/j.1749‐6632.1999.tb07792.x
Justice,	 J.	N.,	Nambiar,	A.	M.,	 Tchkonia,	 T.,	 LeBrasseur,	N.	K.,	 Pascual,	
R.,	 Hashmi,	 S.	 K.,	 Kirkland,	 J.	 L.	 (2019).	 Senolytics	 in	 idiopathic	
pulmonary	 fibrosis:	 Results	 from	 a	 first‐in‐human,	 open‐label,	
pilot study. eBioMedicine,	 40,	 554–563.	 https://doi.org/10.1016/j.
ebiom.2018.12.052
Kahn,	B.	B.,	&	Flier,	J.	S.	(2000).	Obesity	and	insulin	resistance.	Journal 
of Clinical Investigation,	 106,	 473–481.	 https://doi.org/10.1172/
JCI10842
Kadowaki,	 T.,	 Yamauchi,	 T.,	 Kubota,	 N.,	 Hara,	 K.,	 Ueki,	 K.,	 &	 Tobe,	 K.	
(2006).	Adiponectin	and	adiponectin	receptors	in	insulin	resistance,	
diabetes,	and	the	metabolic	syndrome.	Journal of Clinical Investigation,	
116(7),	1784–92.
Kirkland,	J.	L.,	&	Tchkonia,	T.	(2017).	Cellular	senescence:	A	translational	
perspective. EBioMedicine,	 21,	 21–28.	 https://doi.org/10.1016/j.
ebiom.2017.04.01
Kirkland,	 J.	 L.,	 Tchkonia,	 T.,	 Zhu,	 Y.,	 Niedernhofer,	 L.	 J.,	 &	 Robbins,	 P.	





lation of insulin resistance. Nature Medicine,	15,	1082–1087.	https://
doi.org/10.1038/nm.2014
Munoz‐Espin,	 D.,	 &	 Serrano,	 M.	 (2014).	 Cellular	 senescence:	 From	




with cellular senescence in the brain. Aging Cell,	17(6),	e12840.
Ogrodnik,	M.	M.,	Miwa,	S.,	Tchkonia,	T.,	Tiniakos,	D.,	Wilson,	C.	L.,	Lehat,	
A.,	…	Jurk,	D.	(2017).	Cellular	senescence	drives	age‐dependent	he‐
patic steatosis. Nature Communications,	8,	15691.
Ogrodnik,	M.,	Zhu,	Y.,	Prata,	L.,	Tchkonia,	T.,	Krüger,	P.,	Fielder,	E.,	…	Jurk,	
D.	 (2019).	 Obesity‐induced	 cellular	 senescence	 drives	 anxiety‐like	
behavior and impairment of neurogenesis. Cell Metabolism.	 [Epub	
ahead	of	print].	https://doi.org/10.1016/j.cmet.2018.12.008
Okuma,	 A.,	 Hanyu,	 A.,	 Watanabe,	 S.,	 &	 Hara,	 E.	 (2017).	 p16Ink4a and 
p21Cip1/Waf1	promote	tumour	growth	by	enhancing	myeloid‐derived	
suppressor cells chemotaxis. Nature Communications,	8(1),	2050.
Olefsky,	 J.	M.,	 &	Glass,	 C.	 K.	 (2010).	Macrophages,	 inflammation,	 and	
insulin resistance. Annual Review of Physiology,	72,	219–246.	https://
doi.org/10.1146/annurev‐physiol‐021909‐135846
Palmer,	 A.	 K.,	 Tchkonia,	 T.,	 LeBrasseur,	 N.	 K.,	 Chini,	 E.	 N.,	 Xu,	 M.,	 &	
Kirkland,	 J.	 L.	 (2015).	 Cellular	 senescence	 in	 type	 2	 diabetes:	 A	












pulmonary disease. Nature Communications,	 8,	 14532.	 https://doi.
org/10.1038/ncomms14532
Tardelli,	 M.,	 Zeyda,	 K.,	 Moreno‐Viedma,	 V.,	 Wanko,	 B.,	 Grün,	 N.	 G.,	
Staffler,	 G.,	 …	 Stulnig,	 T.	 M.	 (2016).	 Osteopontin	 is	 a	 key	 player	
for local adipose tissue macrophage proliferation in obesity. 
Molecular Metabolism,	 5,	 1131–1137.	 https://doi.org/10.1016/j.
molmet.2016.09.003
Tchkonia,	 T.,	 Morbeck,	 D.	 E.,	 Von	 Zglinicki,	 T.,	 Van	 Deursen,	 J.,	
Lustgarten,	 J.,	 Scrable,	 H.,	 …	 Kirkland,	 J.	 L.	 (2010).	 Fat	 tissue,	
aging,	 and	 cellular	 senescence.	Aging Cell,	9,	 667–684.	 https://doi.
org/10.1111/j.1474‐9726.2010.00608.x
Tchkonia,	 T.,	 Tchoukalova,	 Y.	 D.,	 Giorgadze,	 N.,	 Pirtskhalava,	 T.,	
Karagiannides,	 I.,	 Forse,	R.	A.,	…	Kirkland,	 J.	 L.	 (2005).	Abundance	
of two human preadipocyte subtypes with distinct capacities for 
replication,	 adipogenesis,	 and	 apoptosis	 varies	 among	 fat	 depots.	
American Journal of Physiology‐Endocrinology and Metabolism,	 288,	
E267–277.	https://doi.org/10.1152/ajpendo.00265.2004
     |  15 of 15PALMER Et AL.
Tchkonia,	 T.,	 Thomou,	 T.,	 Zhu,	 Y.,	 Karagiannides,	 I.,	 Pothoulakis,	 C.,	
Jensen,	M.	D.,	&	Kirkland,	J.	L.	(2013).	Mechanisms	and	metabolic	im‐
plications of regional differences among fat depots. Cell Metabolism,	
7,	644–656.
Tesch,	G.	H.	(2007).	Role	of	macrophages	in	complications	of	type	2	dia‐
betes. Clinical and Experimental Pharmacology & Physiology,	34,	1016–
1019.	https://doi.org/10.1111/j.1440‐1681.2007.04729.x
Wilson,	 W.	 H.,	 O'Connor,	 O.	 A.,	 Czuczman,	 M.	 S.,	 LaCasce,	 A.	 S.,	
Gerecitano,	 J.	 F.,	 Leonard,	 J.	 P.,	 …	 Humerickhouse,	 R.	 A.	 (2010).	







genesis and metabolic function in old age. Elife,	4,	e12997.
Xu,	M.,	Pirtskhalava,	T.,	Farr,	J.	N.,	Weigand,	B.	M.,	Palmer,	A.	K.,	Weivoda,	
M.	M.,	…	Kirkland,	J.	L.	(2018).	Senolytics	improve	physical	function	




nescence‐associated	 secretory	 phenotype	 and	 frailty	 in	 old	 age.	
Proceedings of the National Academy of Sciences of the United States of 
America,	112,	E6301–6310.
Yoshimoto,	S.,	 Loo,	T.	M.,	Atarashi,	K.,	Kanda,	H.,	Sato,	S.,	Oyadomari,	
S.,	 …	Ohtani,	 N.	 (2013).	 Obesity‐induced	 gut	microbial	 metabolite	
promotes liver cancer through senescence secretome. Nature,	499,	
97–101.	https://doi.org/10.1038/nature12347
Zaragosi,	L.‐E.,	Wdziekonski,	B.,	Villageois,	P.,	Keophiphath,	M.,	Maumus,	
M.,	Tchkonia,	T.,	…	Dani,	C.	 (2010).	Activin	a	plays	a	critical	 role	 in	



















Additional	 supporting	 information	 may	 be	 found	 online	 in	 the	
Supporting	Information	section	at	the	end	of	the	article.							
How to cite this article:	Palmer	AK,	Xu	M,	Zhu	Y,	et	al.	
Targeting	senescent	cells	alleviates	obesity‐induced	metabolic	
dysfunction. Aging Cell. 2019;18:e12950.  
https://doi.org/10.1111/acel.12950
